Vascepa Sales In Canada And Cost Cuts Will Transform Prospects

AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Published
07 Apr 25
Updated
24 Jul 25
AnalystConsensusTarget's Fair Value
CA$6.40
21.7% undervalued intrinsic discount
24 Jul
CA$5.01
Loading
1Y
64.3%
7D
-0.4%

Author's Valuation

CA$6.4

21.7% undervalued intrinsic discount

AnalystConsensusTarget Fair Value

Shared on01 May 25

Shared on24 Apr 25
Fair value Increased 6.26%

Shared on17 Apr 25
Fair value Increased 2.91%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Decreased 8.55%

AnalystConsensusTarget has decreased profit margin from 2.7% to 0.7%, increased future PE multiple from 97.6x to 358.0x and increased shares outstanding growth rate from -0.0% to -0.0%.